EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

High‐altitude headache: Insights into pathophysiology and potential treatment implications

Marika Falla iD, Florian Frank iD, Giacomo Strapazzon iD, Justin Lawley iD

The Journal of Physiology · 2026-06-03

DOI: 10.1113/jp289704 ↗

At a glance

Übersichtsarbeit in The Journal of Physiology, published online on 2026-06-03. Written by Marika Falla and 3 co-authors. Institution: Institute of Mountain Emergency Medicine, Eurac Research, Bolzano, Italy. Cited 1 times so far (Crossref); 109 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

High‐altitude headache (HAH) is the most common neurological manifestation triggered by hypoxia during rapid ascent above 2500 m, often presenting as an isolated symptom or as part of acute mountain sickness (AMS). HAH shares clinical features with migraine, cluster headache and other primary headache, complicating differential diagnosis. Prevalence varies widely depending on ascent speed and altitude, with higher rates observed in populations ascending rapidly by passive transport and lower rates in those ascending gradually on foot. Controlled normobaric hypoxic chamber studies confirm hypoxia as a potent trigger, with most participants developing HAH within hours. Environmental factors, including fluctuations in barometric pressure, further contribute to headache onset. We propose that the pathophysiology involves activation and sensitization of the trigeminovascular system, with key molecular mediators such as nitric oxide, adenosine, calcitonin gene‐related peptide (CGRP) and pituitary adenylate cyclase‐activating polypeptide (PACAP) playing central roles. Hypoxia stabilizes hypoxia‐inducible factor‐1α (HIF‐1α), driving transcriptional changes that can prime vascular and neuronal pathways for head pain. Although HAH typically responds to simple analgesics and oxygen, its similarity with migraine suggests that targeted therapies against CGRP and PACAP may offer additional benefits. Future research should clarify the mechanistic continuum between HAH and AMS and evaluate multitarget therapeutic approaches. image

Subjects

Author keywords

CGRPPACAPaltitudeheadachehypoxiamigrainesensitizationtrigeminal system

Authors and institutions

  • Institute of Mountain Emergency Medicine, Eurac Research, Bolzano, Italy.
  • Center for Mind/Brain Sciences - CIMeC, University of Trento, Rovereto, Italy.
  • Mountain Clinic, Eurac Research, Bolzano, Italy.
  • Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Medicine - DIMED, University of Padova, Padova, Italy.
  • Institute of Sport Science, Performance Physiology and Prevention, University of Innsbruck, Innsbruck, Austria.

ORCID profiles: Marika Falla, Florian Frank, Giacomo Strapazzon, Justin Lawley

Cite

APA

Falla, M., Frank, F., Strapazzon, G., & Lawley, J. (2026). High‐altitude headache: Insights into pathophysiology and potential treatment implications. The Journal of Physiology. https://doi.org/10.1113/jp289704

Vancouver

Falla M, Frank F, Strapazzon G, Lawley J. High‐altitude headache: Insights into pathophysiology and potential treatment implications. The Journal of Physiology. 2026. doi:10.1113/jp289704

BibTeX
@article{Falla2026,
  author = {Falla, Marika and Frank, Florian and Strapazzon, Giacomo and Lawley, Justin},
  title = {High‐altitude headache: Insights into pathophysiology and potential treatment implications},
  journal = {The Journal of Physiology},
  year = {2026},
  doi = {10.1113/jp289704}
}
Start for free →